Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2009

View Archived Issues

4SC commences phase II 4SC-201 trial in hepatocellular carcinoma

Sitaxsentan treatment has multiple benefits in chronic kidney disease

Pfizer develops novel irreversible and reversible SARS 3CL protease inhibitors

Tumor hypoxia marker [18F]HX4 safe in phase I trial, phase II study planned

Novavax reports preclinical results from ferret study of H1N1 influenza VLP vaccine

Lpath completes enrollment in phase I study of iSonep in wet AMD

Roche reports results for first half 2009

GlaxoSmithKline claims tricyclic nitrogen-containing compounds as antibacterials

Array BioPharma describes Akt protein kinase inhibitors for cancer

Cathepsin K inhibitors identified at Amura for treating bone disorders

Solvay discloses bifeprunox derivatives for PD and other CNS-related disorders

LXR ligands for a variety of potential applications described by Wyeth

Abbott discloses new calpain inhibitors for neurological and other disorders

Focus of gamma-secretase inhibitor PF-3084014 shifts to cancer

Bristol-Myers Squibb identifies potent corticotropin-releasing factor-1 receptor antagonist

Light Sciences Oncology treats patients in phase II Aptocine trial in BPH

Peplin completes enrollment in final phase III ingenol mebutate trial in AK

COTI-2 plus Doxil superior to Doxil alone in animal ovarian cancer model

Amira submits IND for AM-461

Ablynx reports phase I results for subcutaneous administration of ALX-0681

Forest reports phase IIb results for oglemilast in COPD

Pfizer targets the type 1 glycine transporter with PF-3463275 for schizophrenia

Severe lung damage linked to long-term occupational nanoparticle exposure

InterMune and Roche initiate dosing in phase IIb clinical trial of ITMN-191

Gentium reports results from phase III defibrotide trial for sVOD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...